RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Ependymoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Atypical presacral masses in Currarino syndrome: a case series.
Patel Ravi Ameet et al., Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42864507/
- 2.
Chromosome 6q mediated loss of LATS1 tumour suppression as a targetable mechanism of ultra-high-risk posterior fossa A ependymoma.
Donson Andrew M et al., Acta neuropathologica (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42867545/
- 3.
Longitudinal trajectories and determinants of urinary outcomes after spinal ependymoma surgery.
Colonna Stefano et al., European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42867680/
- 4.
Radiation-induced tumor following pencil beam scanning proton therapy for pediatric intracranial ependymoma: a pragmatic analysis of risk factors.
Le Reun Eymeric et al., Journal of radiation research (9 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42623509/
- 5.
EZHIP links neuro-epithelial and mesenchymal tumor programs during progression of PFA ependymoma
Carola Jaunecker et al., Acta Neuropathologica Communications (8 October 2026)
https://doi.org/10.1186/s40478-026-02446-0
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
NCT04730349 · TERMINATED · Phase 1 / Phase 2 · Bristol-Myers Squibb
Up to age 30
https://clinicaltrials.gov/study/NCT04730349
- 2.
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888 · Active (not recruiting) · Phase 2 · National Cancer Institute (NCI)
Ages 12 Months to 21
https://clinicaltrials.gov/study/NCT04320888
- 3.
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04195555 · Active (not recruiting) · Phase 2 · National Cancer Institute (NCI)
Ages 12 Months to 21
https://clinicaltrials.gov/study/NCT04195555
- 4.
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213652 · Active (not recruiting) · Phase 2 · National Cancer Institute (NCI)
Ages 12 Months to 21
https://clinicaltrials.gov/study/NCT03213652
- 5.
COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors
NCT03206021 · Completed · Phase 1 · The Hospital for Sick Children
Ages 1 to 18
https://clinicaltrials.gov/study/NCT03206021
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Ependymoma
Ependymoma is a rare tumour that arises from ependymal cells, which line the fluid-filled spaces of the brain and spinal cord. It can occur in children and adults, and symptoms depend on where it grows. Treatment usually involves surgery to remove as much of the tumour as possible, sometimes followed by radiotherapy. Researchers are studying molecular subtypes to guide care.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
INTRODUCTION: Currarino syndrome is a rare congenital disorder classically defined by the triad of sacral anomaly, anorectal malformation, and a presacral mass. While anterior meningoceles and teratomas are the most commonly reported lesions, an expanding body of literature suggests a broader spectrum of presacral pathology. We present three cases from our institution that expand the phenotypic range of presacral masses associated with Currarino syndrome, including lesions not previously well described in this population. CASE PRESENTATION: Three cases are presented. Final pathologic diagnoses included myxopapillary ependymoma, mature cystic teratoma, and neuroendocrine tumor arising within a teratoma. CONCLUSION: These cases highlight the considerable heterogeneity of presacral lesions in Currarino syndrome and identify two underrecognized or previously unreported tumor types: myxopapillary ependymoma and neuroendocrine tumor. Surgical management must be individualized and often requires a multidisciplinary approach. Future studies will further clarify genotype-phenotype relationships and improve diagnostic and management strategies in this complex syndrome. ESTABLISHED FACTS: Currarino syndrome is a rare congenital disorder classically defined by the triad of sacral anomaly, anorectal malformation, and a presacral mass. Presacral masses are most commonly anterior meningoceles and teratomas. A wider spectrum of lesions has been reported, underscoring the complexity of the syndrome and the importance of thorough evaluation and management of presacral pathology. NOVEL INSIGHTS: In Case 1, we report a previously undescribed association of myxopapillary ependymoma with a retrorectal teratoma in the setting of Currarino syndrome. Case 2 illustrates the potential for significant enlargement of presacral meningoceles with associated teratomas with a rare instance of prenatal diagnosis by ultrasound. Case 3 expands the spectrum of presacral pathology in Currarino syndrome by demonstrating a neuroendocrine tumor.
Common Questions
What is Ependymoma?
Ependymoma is a rare tumour that arises from ependymal cells, which line the fluid-filled spaces of the brain and spinal cord. It can occur in children and adults, and symptoms depend on where it grows. Treatment usually involves surgery to remove as much of the tumour as possible, sometimes followed by radiotherapy. Researchers are studying molecular subtypes to guide care.
How many clinical trials are available for Ependymoma?
RareWays currently indexes 151 clinical trials for Ependymoma, of which 22 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Ependymoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Ependymoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.